CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
adjuvant ultra-hypofractionated radiotherapyradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05850637
NCT05850637Phase 2Completed
CompareCT.gov

Phase II Study to Evaluate the Effectiveness and Toxicity of Adjuvant Ultra-hypofractionated Radiotherapy for the Treatment of Early and Locally Advanced Breast Cancer

Prevent Senior Institute·interventional·Posted May 9, 2023·Updated Apr 4, 2024

In Brief

A Phase 2 clinical trial evaluating adjuvant ultra-hypofractionated radiotherapy for Breast Cancer Female. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Prospective phase 2 study to evaluate the safety and efficacy of ultra-hypofractionated adjuvant radiotherapy in 5 fractions of 5.7 Gy in patients aged over 65 years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer Female
CountriesBrazil
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 9, 2023
Enrollment StartJan 30, 2019
Primary CompletionFeb 11, 2021
Study CompletionApr 1, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 3.1 years ago

Interventions

adjuvant ultra-hypofractionated radiotherapyradiation

adjuvant ultra-hypofractionated radiotherapy for the treatment of early and locally advanced breast cancer